Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06440187Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2018
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by Seoul National University Hospital. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06440187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440187.